CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Product revenue	$ 10,280	$ 7,179	$ 6,263
Funded research and development revenue	13	1,234	2,043
Total revenue	10,293	8,413	8,306
Operating costs and expenses:
Cost of product revenue	3,781	2,930	2,665
Research and product development expenses:
Funded research and product development	25	2,538	4,095
Unfunded research and product development	1,441	1,317	1,349
Total research and product development expenses	1,466	3,855	5,444
Selling, general and administrative expenses	4,994	5,020	3,284
Operating income (loss)	52	(3,392)	(3,087)
Interest expense	0	0	(222)
Loss on extinguishment of debt	0	0	(232)
Gain (loss) on derivatives	73	(3)	(29)
Other (expense) income, net	(25)	3	(2)
Income (loss) before income taxes and non-controlling interest	100	(3,392)	(3,572)
Income tax benefit (expense)	1,548	(4)	208
Net income (loss), net of tax	1,648	(3,396)	(3,364)
Plus: Net loss attributed to non-controlling interest	738	1,638	265
Net income (loss) attributed to MTI	$ 2,386	$ (1,758)	$ (3,099)
Net income (loss) per share attributable to MTI (Basic and Diluted) (in dollars per share)	$ 0.48	$ (0.37)	$ (0.65)
Weighted average shares outstanding (Basic and Diluted) (in shares)	5,001,934	4,771,658	4,771,658